Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2795-2804

  Yamamoto, Kentaroh ^a   Imamura, Hiroshi ^a   Matsuyama, Yutaka ^b   Hasegawa, Kiyoshi ^a   Beck, Yoshifumi ^a   Sugawara, Yasuhiko ^a   Makuuchi, Masatoshi ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; TUMOR MARKER; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER INVASION; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; CANCER STAGING; LIVER TUMOR; METABOLISM; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 73349113221     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0618-y     Document Type: Article

References (38)

1. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
2. Abelev GI, Perova SD, Khramkova NI, et al. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963;1:174-80
3. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-8.
4. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61-6.
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30.
6. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepato-cellular carcinoma. N Eng J Med. 1984;310:1427-31.
7. Tanabe Y, Ohnishi K, Nomura F, et al. Plasma abnormal pro-thrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol. 1988;83:1386-9.
8. Fujiyama S, Izuno K, Gohshi K, et al. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepa-tocellular carcinoma. Dig Dis Sci. 1991;36:1787-92.
9. Grazi GL, Mazziotti A, Legnani C, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with spe-cial reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1995;1:249-55.
10. Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-car-boxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocel-lular carcinoma. Am J Gastroenterol. 1999;94:650-4.
11. Tsai SL, Huang GT, Yang PM, et al. Plasma des-gamma-car-boxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology. 1990;11:481-8.
12. Deyashiki Y, Nishioka Y, Takahashi K, et al. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocel-lular carcinoma. Cancer. 1989;64:2546-51.
13. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci. 1993;38:2170-6.
14. Inoue S, Nakao A, Harada A, et al. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol. 1994;89:2222-6.
15. Lamerz R, Runge M, Stieber P, et al. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999;19:2489-93.
16. Cui R, He J, Zhang F, et al. Diagnostic value of protein induced by vitamin K absence (PIVKA-II) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003;88:1878-82.
17. Wang CS, Lin CL, Lee HC, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular car-cinoma. World J Gastroenterol. 2005;11:6115-9.
18. Mita Y, Aoyagi Y, Yanagi M, et al. The usefulness of deter-mining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocel-lular carcinoma. Cancer. 1998;82:1643-8.
19. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma varies according to tumor size. Am J Gastroenterol. 2006;101:2038-43.
20. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxypro-thrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepa-tology. 2003;37:1114-21.
21. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer. 1994;73:2464-71.
22. Carr BI, Kanke F, Wise M, et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776-82.
23. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145-59.
24. Imamura H, Matsuyama Y, Miyagawa Y, et al. Prognostic sig-nificance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999;86:1032-8.
25. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214-9.
26. Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clini-copathologic features of solitary hepatocellular carcinoma. Cancer. 2000;88:544-9.
27. Oishi K, Itamoto T, Amano H, et al. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95:311-6.
28. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immuno-therapy to lower postsurgical recurrence rate of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356:802-7.
29. Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2:17-30
30. Liver Cancer Study Group in Japan. The general rules for the clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara;2000.
31. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1998;8:283-98.
32. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker devel-opment for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61.
33. Nakao A, Suzuki Y, Issiki K, et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroen-terol. 1991;86:62-6.
34. Lefrere JJ, Gozin D, Lerable J, et al. Des-gamma-carboxypro-thrombin assay in alcoholic cirrhotic patients with alpha-fetoprotein level slightly increased. Hepatology. 1986;6:1066-7.
35. Ohhira M, Ohtake T, Saito H, et al. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res. 1999;23:67S-70S.
36. Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic signifi-cance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol. 1999;14:281-6.
37. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7.
38. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prog-nosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-7.